Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

University Hospital Regensburg

Status: Completed

Conditions: Glioblastoma; Angiogenesis

Treatments: Other: Observation of neurological deficits

Study type: Observational

Funder types: Other

Identifiers

NCT04974983

Z-2017-0901-5

Details and patient eligibility

About

This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.

Enrollment: 203 patients

Sex

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Diagnosis of recurrent glioblastoma

Exclusion criteria

Severe neurocognitive deficits

Trial design

203 participants in 2 patient groups

A

Description:

Treatment without bevacizumab

Treatment:

Other: Observation of neurological deficits

B

Description:

Treatment with bevacizumab

Treatment:

Other: Observation of neurological deficits